Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

Annals of the New York Academy of Sciences

Volumn 1005, Issue , 2003, Pages 423-430

  Silva, D G ^a,b   Charlton, B ^b   Cowden, W ^b   Petrovsky, N ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b Biology and Environment   (Australia)

Author keywords

Autoimmune diabetes; Immunostimulation; QFA; Type 1 diabetes; Vaccine development

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; IMMUNOSTIMULATING AGENT; PLACEBO; Q FEVER COMPLEMENT FIXING ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

MYCOBACTERIUM BOVIS BCG;

EID: 1942474600     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1288.072     Document Type: Conference Paper

References (41)

1. ZIMMET, P.Z., T. TUOMI, I.R. MACKAY et al. 1994. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet. Med. 11: 299-303.
2. ASSAN, R., G. FEUTREN, M. DEBRAY-SACHS et al. 1985. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1: 67-71.
3. STILLER, C.R., J. DUPRE, M. GENT et al. 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362-1367.
4. CAREL, J.C., C. BOITARD, G. EISENBARTH et al. 1996. Cyclosporine delays, but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J. Autoimmunol. 9: 739-745.
5. CHATENOUD, L., J. PRIMO & J.F. BACH. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158: 2947-2954.
6. CASTEELS, K.M., C. MATHIEU, M. WAER et al. 1998. Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 139: 95-102.
7. JAKUBOWSKI, A., B.N. EHRENFELS, R.B. PEPINSKY & L.C. BURKLY. 1995. Vascular cell adhesion molecule-Ig fusion protein selectively targets activated alpha 4-integrin receptors in vivo: inhibition of autoimmune diabetes in an adoptive transfer model in nonobese diabetic mice. J. Immunol. 155: 938-946.
8. KOMMAJOSYULA, S., S. REDDY, K. NITSCHKE et al. 2001. Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy. J. Leukocyte Biol. 70: 510-517.
9. MORIYAMA, H., K. YOKONO, K. AMANO et al. 1996. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/ intercellular adhesion molecule-1 pathway. J. Immunol. 157: 3737-3743.
10. LAMPETER, E.F., A. KLINGHAMMER, W.A. SCHERBAUM et al. 1998. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes - DENIS Group. Diabetes 47: 980-984.
11. TIAN, J., M.A. ATKINSON, M. CLARE-SALZLER et al. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1561-1567.
12. POLANSKI, M., N.S. MELICAN, J. ZHANG & H.L. WEINER. 1997. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J. Autoimmunol. 10: 339-346.
13. HANNINEN, A. 2000. Prevention of autoimmune type 1 diabetes via mucosal tolerance: is mucosal autoantigen administration as safe and effective as it should be? Scand. J. Immunol. 52: 217-225.
14. FUCHTENBUSCH, M., W. RABL, B. GRASSL et al. 1998. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41: 536-541.
15. POZZILLI, P. & M. GISELLA CAVALLO. 2000. Oral insulin and the induction of tolerance in man: reality or fantasy? Diabetes Metab. Res. Rev. 16: 306-307.
16. Yu, L., D.D. CUTHBERTSON, N. MACLAREN et al. 2001. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 50: 1735-1740.
17. CHANDY, K.G., A.M. CHARLES, A. KERSHNAR et al. 1984. Autologous mixed lymphocyte reaction in man: XV. Cellular and molecular basis of deficient autologous mixed lymphocyte response in insulin-dependent diabetes mellitus. J. Clin. Immunol. 4: 424-428.
18. GUPTA, S., S. FIKRIG & E. ORTI. 1983. Autologous mixed lymphocyte reaction in man: VI. Deficiency of autologous mixed lymphocyte reaction in type I (insulin-dependent) diabetes mellitus. J. Clin. Lab. Immunol. 11: 59-62.
19. RASANEN, L., H. HYOTY, M. LEHTO et al. 1989. Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. Clin. Immunol. Immunopathol. 52: 406-413.
20. BUSCHARD, K., S. MADSBAD & J. RYGAARD. 1980. Depressed suppressor cell activity in patients with newly diagnosed insulin-dependent diabetes mellitus. Clin. Exp. Immunol. 41: 25-32.
21. JANSEN, A., M. VAN HAGEN & H.A. DREXHAGE. 1995. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 345: 491-492.
22. CRISA, L., J.P. MORDES & A.A. ROSSINI. 1992. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab. Rev. 8: 4-37.
23. SERREZE, D.V., H.R. GASKINS & E.H. LEITER. 1993. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J. Immunol. 150: 2534-2543.
24. SERREZE, D.V. & E.H. LEITER. 1988. Defective activation of T suppressor cell function in nonobese diabetic mice: potential relation to cytokine deficiencies. J. Immunol. 140: 3801-3807.
25. JACOB, C.O., Z. FRONEK, G.D. LEWIS et al. 1990. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 87: 1233-1237.
26. LANGMUIR, P.B., M.M. BRIDGETT, A.L. BOTHWELL & I.N. CRISPE. 1993. Bone marrow abnormalities in the non-obese diabetic mouse. Int. Immunol. 5: 169-177.
27. TOYOTA, T., J. SATOH, K. OYA et al. 1986. Streptococcal preparation (OK-432) inhibits development of type 1 diabetes in NOD mice. Diabetes 35: 496-499.
28. MCINERNEY, M.F., S.B. PEK & D.W. THOMAS. 1991. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40: 715-725.
29. SADELAIN, M.W., H.Y. QIN, J. LAUZON & B. SINGH. 1990. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589.
30. QIN, H.Y. & B. SINGH. 1997. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J. Autoimmunol. 10: 271-278.
31. HARADA, M., Y. KISHIMOTO & S. MAKINO. 1990. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabet. Res. Clin. Pract. 8: 85-89.
32. ELIAS, D., A. MEILIN, V. ABLAMUNITS et al. 1997. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 46: 758-764.
33. RAZ, I., D. ELIAS, A. AVRON et al. 2001. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (Diapep277): a randomised, double-blind, phase II trial. Lancet 358: 1749-1753.
34. SHEHADEH, N., F. CALCINARO, B.J. BRADLEY et al. 1994. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343: 706-707.
35. ALLEN, H.F., G.J. KLINGENSMITH, P. JENSEN et al. 1999. Effect of bacillus Calmette-Guérin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care 22: 1703-1707.
36. ELLIOTT, J.F., K.L. MARLIN & R.M. COUCH. 1998. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 21: 1691-1693.
37. HEGGERS, J.P., L.P. MALLAVIA & D.J. HINRICHS. 1974. The cellular immune response to antigens of Coxiella burnetii. Can. J. Microbiol. 20: 657-662.
38. JERRELLS, T.R., L.P. MALLAVIA & D.J. HINRICHS. 1975. Detection of long-term cellular immunity to Coxiella burnetii as assayed by lymphocyte transformation. Infect. Immunol. 11: 280-286.
39. Izzo, A.A. & B.P. MARMION. 1993. Variation in interferon-gamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects. Clin. Exp. Immunol. 94: 507-515.
40. CLARK, I.A. 1979. Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect. Immunol. 24: 319-325.
41. WAAG, D.M., M. KENDE, T.A. DAMROW et al. 1990. Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann. N.Y. Acad. Sci. 590: 203-214.